ESR1 and breast carcinoma: Inhibition of the PI3K/AKT/mTOR signaling pathway has been shown to augment the response of ER+ breast cancer to ET, indicating that dual targeting of the ER and PI3K/AKT/mTOR pathways may be another rational treatment approach119,120.